The PlexCMV tests the risk of cytomegalovirus infection and transplant infection by measuring changes in T-cell immunity to the virus, according to an Oct. 17 news release from the company.
The test assesses the risk of losing the transplanted organ and fluctuations of the risk during therapy.
